Enterolax-Stoma (sodium picosulfate) tablets 7.5 mg. №10


Manufacturer: Ukraine

Constipation or cases requiring relief of defecation. Like other laxatives, ENTRELACS should not be used daily or for an extended period without establishing the cause of the constipation.



Enterolax-Stoma Composition
active substance: sodium picosulfate;

1 tablet contains sodium picosulfate in terms of anhydrous substance 7.5 mg;

Excipients: lactose monohydrate, potato starch, povidone, magnesium stearate.

Enterolax-Stoma Dosage form


Main physical and chemical properties: tablets of white or almost white color with a biconvex surface.

Pharmacotherapeutic group

Contact laxatives. Sodium picosulfate.

Pharmacological properties


Contact laxative of the triarylmethane group.

Sodium picosulfate after bacterial cleavage in the colon stimulates its mucous membrane, accelerating peristalsis, promotes the accumulation of water and electrolytes in the lumen of the colon. This results in stimulation of defecation, reduction of passage time and softening of feces.


Sodium picosulfate is not absorbed from the digestive tract and is not subject to hepato-intestinal circulation.

The active metabolite of bis- (p-hydroxyphenyl) -pyridyl-2-methane is formed after bacterial cleavage in the colon, the action of ENTEROLAX usually begins 6-12 hours after ingestion, depending on the release of the active metabolite. After oral administration, only a small amount of the drug can be detected in organs and systems of the body. The laxative effect of the drug does not correlate with the level of the active metabolite in blood plasma.

Ability to influence the speed of reaction when driving a car or working with other mechanisms

Adverse reactions such as dizziness and / or syncope may develop as a result of a vasovagal reaction (including abdominal spasm). In case of abdominal spasm, the patient should avoid such potentially dangerous activities as driving or other mechanisms.

Constipation or cases that require facilitation of defecation.

Like other laxatives, ENTEROLAX should not be used daily or for long periods without a complete diagnostic evaluation to determine the cause of constipation.

Hypersensitivity to the active substance, to other triarylmethanes or to any of the excipients.
Dynamic or mechanical intestinal obstruction or acute abdominal disease, such as appendicitis.
Acute inflammatory bowel disease.
Acute abdominal pain accompanied by nausea and vomiting and may indicate the above acute illness.
Severe dehydration.
Rare hereditary intolerance to any of the excipients, for example, there is a possibility of undiagnosed lactose intolerance (see section 4.4).
Interaction with other medicinal products and other forms of interaction

Concomitant use with diuretics and glucocorticoids increases the risk of water-electrolyte disorders, including hypokalemia. Possible deterioration of the tolerability of cardiac glycosides. Broad-spectrum antibiotics can reduce the laxative effect of sodium picosulfate.